Vir Biotechnology (NASDAQ:VIR)報告季度每股虧損$(0.76)，優於分析師普遍預期的$(0.87)，增長了12.64%。較去年同期的每股虧損$(0.86)提高了11.63%。公司報告季度銷售額爲$12.37M，超過了分析師普遍預期的$8.14M，增長了52.01%。與去年同期的銷售額$16.79M相比，減少了26.29%。
以上內容來自Benzinga Earnings專欄，原文如下：
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.87) by 12.64 percent. This is a 11.63 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $12.37 million which beat the analyst consensus estimate of $8.14 million by 52.01 percent. This is a 26.29 percent decrease over sales of $16.79 million the same period last year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。